Recent News

• 06.04.2026 - Notice of Annual General Meeting of Shareholders (AGM) to be held on June 30, 2026
• 06.04.2026 - Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026
• 06.04.2026 - Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026
• 05.28.2026 - Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance
• 05.28.2026 - Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance
• 05.21.2026 - Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models
• 05.21.2026 - Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models
• 05.21.2026 - Akari Therapeutics Announces $5.5 Million Private Placement Offering
• 05.21.2026 - Akari Therapeutics Announces $5.5 Million Private Placement Offering
• 05.18.2026 - Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase

Recent Filings

• 06.04.2026 - DEF 14A Other definitive proxy statements
• 06.03.2026 - D Notice of Exempt Offering of Securities
• 05.22.2026 - PRE 14A Other preliminary proxy statements
• 05.22.2026 - 8-K Current report
• 05.21.2026 - RW Registration Withdrawal Request
• 05.19.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.18.2026 - NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB